Change is afoot at the world’s largest drug company. After safety concerns led Pfizer (New York, NY) to halt development of Torcetrapib, the blockbuster cholesterol drug in which it invested $800 million, the company has been scrambling to refocus itself. As Pfizer seeks to fill the gaps in its pipeline, it is hungry for acquisitions in the areas of "diabetes, neurology, infectious disease, and oncology that combined have a worldwide market potential significantly in excess of $200 billion," according to management.

Subscribers: click here for the full story

Non-Subscribers: click here to subscribe

February 2007 - Table of Contents

DTTR February 2007 (full PDF issue)

Siemens, GE Build Diagnostic Powerhouses

FDA to Hold Meeting on IVDMIA Draft Guidance

Pfizer Buys Diagnostic Rights for Genizon’s Disease Markers

New ACOG Guidelines Urge Earlier Screening for Down Syndrome

FDA Approves Ortho-Clinical’s Chagas Disease Screening Test

Initiative Seeks Routine SCID Screening for Newborns

Genomic Health Gets United, Aetna Reimbursement for Oncotype DX

Pharmacogenomics: Are Labs Believing the Hype?

JAMA Study Links Expanded Medicare Reimbursement With Increased Colon Cancer Screening, Earlier Diagnosis

Epigenomics Chooses New CEO, Contracts With Centocor for Cancer Biomarkers

Luminex to Buy Tm Bioscience for $37.9M

BD Closes on $350m TriPath Acquisition

IVD Stocks Rose 20% in 2006 Led by Immucor, Cholestech, Digene

Molecular Diagnostics: The Conference